⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7206474 | 0.89 | — | — | |
| SCHEMBL7305737 | 0.88 | — | — | |
| SCHEMBL7305731 | 0.88 | — | — | |
| SCHEMBL31388212 | 0.84 | — | — | |
| SCHEMBL31388220 | 0.84 | — | — | |
| SCHEMBL30988080 | 0.83 | — | — | |
| SCHEMBL7307500 | 0.83 | — | — | |
| SCHEMBL7207797 | 0.83 | — | — | |
| SCHEMBL30579503 | 0.81 | — | — | |
| SCHEMBL7307779 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6638941-B1 | Spirolactam compounds useful as inhibitors of protein-protein interactions modulated by SH3 domains are disclosed. Compounds of the invention are also useful as beta-turn mimetics. Disclosed are libraries of compounds of the invention, and | OSI PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
| WO-1998054208-A1 | CONFORMATIONALLY CONSTRAINED PEPTIDOMIMETICS AS β-TURN TEMPLATES AND MODULATORS OF SH3 DOMAINS | CADUS PHARMACEUTICAL CORPORATION (US) | 1998-12-03 | — | — | WO | disclosed |